Edition:
United States

Alere Inc (ALR)

ALR on New York Consolidated

49.85USD
26 Sep 2017
Change (% chg)

$-0.45 (-0.89%)
Prev Close
$50.30
Open
$50.31
Day's High
$50.40
Day's Low
$49.44
Volume
4,568,826
Avg. Vol
1,445,578
52-wk High
$50.64
52-wk Low
$34.41

Latest Key Developments (Source: Significant Developments)

Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE
Monday, 18 Sep 2017 08:28pm EDT 

Sept 18 (Reuters) - Alere Inc :Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott.Announced intention to voluntarily delist its Series B Convertible Perpetual Preferred Stock, par value $0.001 per share.Voluntary delisting is subject to and conditioned upon completion of acquisition by Abbott Laboratories, an Illinois corporation.  Full Article

Alere's unit Arriva Medical receives notice that medicare enrollment will be revoked by CMS
Friday, 4 Nov 2016 11:45am EDT 

Alere Inc : Alere - on oct 12, co's unit arriva medical received notice, dated oct 5, that medicare enrollment will be revoked by CMS - sec filing . Alere-Notice by CMS, based on CMS’ assertion that, over 5-year period, unit had allegedly submitted claims for 211 deceased patients . Alere - CMS letter only identifies 47 of the 211 claims . Alere - initial appeal of determination denied by cms on nov 2, and, therefore, arriva’s medicare enrollment will be revoked effective november 4 . Alere - conducted initial investigation into issue, do not believe that arriva received or retained improper reimbursement for DME items furnished .Alere-"continuing to work through the appeals process, with the goal that arriva’s enrollment status will be reactivated retroactively to november 4".  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

Alere Q2 loss per share $0.46 from continuing operations
Tuesday, 6 Sep 2016 07:00am EDT 

Alere Says With Filing Of Q2 2016 Form 10 : Alere reports second quarter 2016 financial results . Q2 revenue $611 million versus I/B/E/S view $607.4 million . Q2 loss per share $0.46 from continuing operations . Q2 earnings per share view $0.58 -- Thomson Reuters I/B/E/S .Alere says with filing of Q2 2016 form 10-Q now current in financial filings and are on track to report our Q3 2016 results within normal time frame.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alere says filed a complaint against Abbott on Aug. 25
Friday, 26 Aug 2016 11:00am EDT 

Alere Inc : Alere issues statement . "on August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery court" . Says expect redacted version of complaint to be publicly available next week . Expect redacted version of complaint to be publicly available next week .Alere will "compel" Abbott to complete transaction in accordance with its terms.  Full Article

Alere gets FDA clearance for its RSV rapid molecular test
Friday, 19 Aug 2016 07:00am EDT 

Alere Inc : Alere receives FDA clearance for Alere™ I RSV rapid molecular test . Alere will shortly submit an application for clia waiver of Alere I RSV test .Alere I testing applications have previously been clia-waived for Influenza a & b and strep a.  Full Article

Alere entered into a second amendment to secured credit agreement
Thursday, 18 Aug 2016 05:13pm EDT 

Alere Inc : On August 18 entered into a second amendment to secured credit agreement .Second amendment extends the deadline for delivery of the Q2 financial reports to September 13, 2016 - sec filing.  Full Article

Alere Q1 loss per share $0.18 from continuing operations
Wednesday, 17 Aug 2016 06:15am EDT 

Alere Inc : Q1 earnings per share view $0.56, revenue view $602.6 million -- Thomson Reuters I/B/E/S . Based on current business outlook, expect improved organic revenue growth in q2 and second half of 2016 . Amendment to secured credit agreement to provide extension of date by co will file q2 financial statements under secured credit agreement to sept 13 . Currently plans to file q2 form 10-q by sept 13, 2016, expects to pay about $3 million in fees to obtain amendment to secured credit amendment . Revenue for q1 of 2016 was $578 million, a 6% decrease compared to $613 million in prior year period .Company is seeking an amendment to its secured credit agreement.  Full Article

Alere achieves IVD CE mark for Alere reader lateral flow assay analyzer
Tuesday, 9 Aug 2016 07:00am EDT 

Alere Inc : Alere achieves IVD CE mark for its Alere™ reader lateral flow assay analyzer .Alere reader will launch initially in Europe, with other regions to follow.  Full Article

BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE

* Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott